Microsaic Systems plc (LON:MSYS), the developer of point of need mass spectrometry instruments, has today announced that it has signed an agreement with Rightek Co., Ltd. The Agreement covers the distribution
Microsaic’s latest product innovation, the 4500 MiD®, has been featured in a mass spectrometry article in Nature Product Focus. Optimize productivity Designed to bring real-time mass detection to laboratories and processing facilities,
Microsaic Systems plc (LON:MSYS), the developer of point of need mass spectrometry instruments, announced today that it has signed a Heads of Terms agreement (“HoT”) with Knauer Wissenschaftliche Geräte GmbH (“Knauer”).
Microsaic Systems plc (LON:MSYS), the developer of point of need mass spectrometry (“MS”) instruments, has today announced that its Annual General Meeting will be held at 11.00 a.m. on 4
Microsaic Systems PLC (LON:MSYS), the developer of point of need mass spectrometry (“MS”) instruments, has today announced that it has signed an agreement with Unimicro Technologies Inc. (“Unimicro”)(the “Agreement”). The
Microsaic Systems plc (LON:MSYS), the developer of point of need mass spectrometry instruments, has today announced a commercial contract with UK based technology and innovation centre, the Centre for Process Innovation
Microsaic Systems’ Glenn Tracey discusses their full year results for the year ended 31 December 2017 in this exclusive interview with DirectorsTalk
Microsaic Systems Plc (LON:MSYS) CEO Glenn Tracey talks to DirectorsTalk about its full year results for the year ended 31st Dec 2017. Glenn talks us through the highlights, explains how
Microsaic Systems plc (AIM: MSYS), the developer of chip-based mass spectrometry instruments, announced this morning its audited financial results for the year ended 31 December 2017. Glenn Tracey, CEO, commented: “The
Microsaic Systems plc (LON:MSYS), the developer of chip-based mass spectrometry instruments, has today announced that the Company will be reporting final results for the 12 months ended 31 December 2017
© 2023 – DirectorsTalk. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.
